Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

about

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.

P2860

Q47169141-6CE938D4-45D4-44AE-AFF8-EB89C3193888

P2860

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

Item

http://www.wikidata.org/entity/Q38649485

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Ribociclib for the treatment o ...... , HER2-negative breast cancer.

@en

type

Item

label

Ribociclib for the treatment o ...... , HER2-negative breast cancer.

@en

prefLabel

Ribociclib for the treatment o ...... , HER2-negative breast cancer.

@en

P1476

Ribociclib for the treatment o ...... , HER2-negative breast cancer.

@en

P2093

Isabel Echavarria

http://www.w3.org/2001/XMLSchema#string

Miguel Martin

http://www.w3.org/2001/XMLSchema#string

Yolanda Jerez

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

Targeting CDK4/6 in patients with cancer

Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

P304

2137-2149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0183

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sara López-Tarruella

I Marquez-Rodas

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28758424

http://www.w3.org/2001/XMLSchema#string

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

about

P2860

P2860

Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698